Alumis (NASDAQ:ALMS – Get Free Report)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports.
Several other analysts also recently issued reports on ALMS. SVB Leerink started coverage on Alumis in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target for the company. Leerink Partnrs upgraded Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Morgan Stanley assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, Guggenheim began coverage on shares of Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Alumis currently has a consensus rating of “Buy” and a consensus target price of $27.50.
Read Our Latest Stock Analysis on Alumis
Alumis Price Performance
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in shares of Alumis in the second quarter valued at approximately $3,376,000. Towerview LLC acquired a new position in Alumis during the 2nd quarter valued at $4,123,000. Ally Bridge Group NY LLC bought a new stake in Alumis in the 2nd quarter valued at $8,229,000. Yu Fan acquired a new stake in Alumis in the 2nd quarter worth $10,502,000. Finally, SR One Capital Management LP bought a new position in shares of Alumis during the 2nd quarter worth about $26,067,000.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
- Five stocks we like better than Alumis
- Golden Cross Stocks: Pattern, Examples and Charts
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Options Trading – Understanding Strike Price
- Lowe’s Stock: Hold Now, Buy it When it Dips
- 3 Grocery Stocks That Are Proving They Are Still Essential
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.